iCardiac Launches “PFT Global” Service Line
News Apr 15, 2016
iCardiac Technologies, Inc., has unveiled “PFT Global”, the new name of its respiratory testing service line. The move completes a six-month process of integrating the clinical trials division of nSpire Health, which was acquired in July 2015, into the iCardiac organization. It also reflects the broader respiratory service capabilities that were enabled by the acquisition.
The newly named PFT Global service line continues to be a leader in respiratory clinical research, having captured over 10 million pulmonary function tests worldwide over the past 10 years and supporting research sites in over 60 countries. The business is focused on supporting clinical trials in Phase II and III. This includes study sizes ranging from two sites and 50 patients to global-scale pivotal projects covering 30 countries with 750 clinical sites and 14,000 subjects.
“This renaming was the culmination of our comprehensive efforts to integrate our acquired respiratory services into iCardiac,” said John Sage, Senior Vice President of Respiratory and ePRO at iCardiac. “As a result of the integration, our sponsors will benefit from various enhanced capabilities, including our broader capacity and resources in relation to project management, site support, and global logistics.”
“This new name of our respiratory service line represents a company milestone and symbolizes what we offer to sponsors,” said Alex Zapesochny, President and CEO of iCardiac. “Over the years we have become a company with superb global capabilities, and we offer an expertise in pulmonary function testing that is second to none.”
About iCardiac Technologies:
iCardiac Technologies, Inc. is an industry-leading centralized core laboratory for respiratory and cardiac safety services. Its high precision cardiac safety assessment methodology has set a new standard for precision and accuracy in all phases of clinical trials. The company serves 8 of the top 10 global pharmaceutical companies, as well as numerous small and mid-sized pharma and biotechnology firms. For more information, please visit: www.icardiac.com.
In the largest study of its kind, researchers at Newcastle University have led national research into the treatment of patients with newly diagnosed myeloma. The results, published by The Lancet Oncology, show an improvement for those who received ongoing therapy with a drug called lenalidomide, compared to those not receiving it.READ MORE
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019